Kebapcilar, Ayse G.Ilhan, Tolgay T.Dursunoglu, DuyguKebapcilar, LeventIpekci, Suleyman H.Baldane, SuleymanUcar, Mustafa G.2020-03-262020-03-2620170951-35901473-0766https://dx.doi.org/10.1080/09513590.2017.1320384https://hdl.handle.net/20.500.12395/35058This study hypothesizes that oral rosuvastatin, oral dienogest and intraperitoneal bevacizumab might improve endometriosis in randomly selected female Wistar albino rats with surgically endometriotic implants. Thirty female Wistar albino rats with surgically endometriotic implants were randomized into three treatment groups: oral rosuvastatin (20mg kg/day; oral rosuvastatin group 1; n=10), oral progesterone (dienogest group 2; n=10) and intraperitoneal bevacizumab (2.5mg/kg of single intraperitoneal injection of bevacizumab; bevacizumab group 3; n=10), for 10 days. Post-treatment variables were compared. The oral rosuvastatin group showed higher reduction for the glandular epithelium and uterine vessels of histopathological scores values than the oral progesterone group (both, p<0.017, respectively). The median glandular epithelium and uterine vessels and histopathological scores values did not show a statistically significant difference between group 1 and group 3 (p>0.017). Endometrial thickness values and uterine volume values were more significantly reduced in the oral rosuvastatin group than the oral progesterone group (both, p<0.017, respectively). Moreover, endometrial thickness and uterine volume values were not different in groups wecompared with group 3 (p>0.017). In conclusion, oral rosuvastatin and intraperitoneal injection of bevacizumab may cause more significant regression of surgically endometriotic implants in rats than oral progesterone medications.en10.1080/09513590.2017.1320384info:eu-repo/semantics/closedAccessBevacizumabendometriotic implantsoral progesteroneoral rosuvastatinArticle331292392728452240Q2WOS:000415656400005Q4